Novartis/GSK mega-deal to prompt copycat dealmaking?
This article was originally published in Scrip
Executive Summary
It's not something you wake up to every day. After a relatively quiet holiday weekend with only rumors of a Pfizer/AstraZeneca mega-merger to liven things up (scripintelligence.com, 21 April 2014), Novartis and GlaxoSmithKline (and Eli Lilly) announced a deal that had everyone rubbing their eyes and taking a closer look (scripintelligence.com, 22 April 2014). In the words of GSK's CEO Sir Andrew Witty: "We needed the planets to align, and that's what's happened here."
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.